Orrick Tech Companies Team Advises Cortexyme in $76 Million Series B Financing


Orrick has advised Cortexyme on its $76 million Series B financing round. San-Francisco based Cortexyme is a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and other degenerative diseases.

Orrick has been advising Cortexyme since its Series A financing and continues to counsel the company on various aspects of its business, including on corporate and trademark matters.

The Orrick team was led by Tech Companies Group partner Scott Iyama and included associates Laura Bloxham and Brigid McCurdy.

For additional information on the financing, please see Cortexyme’s press release.